These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39154795)

  • 1. Multiple Biomarkers Are Equivalent to Clinical Pulmonary Arterial Hypertension Survival Risk Models.
    Griffiths M; Simpson CE; Yang J; Vaidya D; Nies MK; Brandal S; Damico R; Hassoun P; Ivy DD; Austin ED; Pauciulo MW; Lutz KA; Martin LJ; Rosenzweig EB; Benza RL; Nichols WC; Manlhiot C; Everett AD
    Chest; 2024 Aug; ():. PubMed ID: 39154795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.
    Simpson CE; Damico RL; Hassoun PM; Martin LJ; Yang J; Nies MK; Vaidya RD; Brandal S; Pauciulo MW; Austin ED; Ivy DD; Nichols WC; Everett AD
    Chest; 2020 Jun; 157(6):1606-1616. PubMed ID: 31987881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
    Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CT-IGFBP-4 as a novel prognostic biomarker in acute heart failure.
    Konev AA; Kharitonov AV; Rozov FN; Altshuler EP; Serebryanaya DV; Lassus J; Harjola VP; Katrukha AG; Postnikov AB
    ESC Heart Fail; 2020 Apr; 7(2):434-444. PubMed ID: 31967738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative and added prognostic value of biomarkers to the Revised Cardiac Risk Index for preoperative prediction of major adverse cardiac events and all-cause mortality in patients who undergo noncardiac surgery.
    Vernooij LM; van Klei WA; Moons KG; Takada T; van Waes J; Damen JA
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013139. PubMed ID: 34931303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asymmetric Dimethylarginine and NT-proBNP Levels Provide Synergistic Information in Pulmonary Arterial Hypertension.
    Shafran I; Probst V; Panzenböck A; Sadushi-Kolici R; Gerges C; Wolzt M; Segel MJ; Celermajer DS; Lang IM; Skoro-Sajer N
    JACC Heart Fail; 2024 Jun; 12(6):1089-1097. PubMed ID: 38573264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma insulin-like growth factor binding protein 1 in pulmonary arterial hypertension.
    Bouzina H; Hesselstrand R; Rådegran G
    Scand Cardiovasc J; 2021 Feb; 55(1):35-42. PubMed ID: 32597241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension.
    Rhodes CJ; Wharton J; Swietlik EM; Harbaum L; Girerd B; Coghlan JG; Lordan J; Church C; Pepke-Zaba J; Toshner M; Wort SJ; Kiely DG; Condliffe R; Lawrie A; Gräf S; Montani D; Boucly A; Sitbon O; Humbert M; Howard LS; Morrell NW; Wilkins MR
    Am J Respir Crit Care Med; 2022 May; 205(9):1102-1111. PubMed ID: 35081018
    [No Abstract]   [Full Text] [Related]  

  • 10. The angiostatic peptide endostatin enhances mortality risk prediction in pulmonary arterial hypertension.
    Simpson CE; Griffiths M; Yang J; Nies MK; Vaidya RD; Brandal S; Martin LJ; Pauciulo MW; Lutz KA; Coleman AW; Austin ED; Ivy DD; Nichols WC; Everett AD; Hassoun PM; Damico RL
    ERJ Open Res; 2021 Oct; 7(4):. PubMed ID: 34651041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Right ventricular expression of NT-proBNP adds predictive value to REVEAL score in patients with pulmonary arterial hypertension.
    Chang WT; Shih JY; Hong CS; Lin YW; Chen YC; Ho CH; Chen ZC; Roan JN; Hsu CH
    ESC Heart Fail; 2021 Aug; 8(4):3082-3092. PubMed ID: 33955184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.
    Benza RL; Kanwar MK; Raina A; Scott JV; Zhao CL; Selej M; Elliott CG; Farber HW
    Chest; 2021 Jan; 159(1):337-346. PubMed ID: 32882243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble ST2 and N-terminal pro-brain natriuretic peptide combination. Useful biomarker for predicting outcome of childhoodpulmonary arterial hypertension.
    Chida A; Sato H; Shintani M; Nakayama T; Kawamura Y; Furutani Y; Inai K; Saji T; Matsuoka R; Nonoyama S; Nakanishi T
    Circ J; 2014; 78(2):436-42. PubMed ID: 24304538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension.
    Haddad F; Contrepois K; Amsallem M; Denault AY; Bernardo RJ; Jha A; Taylor S; Arthur Ataam J; Mercier O; Kuznetsova T; Vonk Noordegraaf A; Zamanian RT; Sweatt AJ
    Chest; 2022 May; 161(5):1347-1359. PubMed ID: 34774527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension.
    Rhodes CJ; Wharton J; Howard LS; Gibbs JS; Wilkins MR
    Heart; 2011 Jul; 97(13):1054-60. PubMed ID: 21558476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of Acute Physiology and Chronic Health Evaluation II score, early lactate area, and N-terminal prohormone of brain natriuretic peptide levels as a predictor of mortality in geriatric patients with septic shock.
    Wang H; Li Z; Yin M; Chen XM; Ding SF; Li C; Zhai Q; Li Y; Liu H; Wu DW
    J Crit Care; 2015 Apr; 30(2):304-9. PubMed ID: 25499413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating angiogenic modulatory factors predict survival and functional class in pulmonary arterial hypertension.
    Malhotra R; Paskin-Flerlage S; Zamanian RT; Zimmerman P; Schmidt JW; Deng DY; Southwood M; Spencer R; Lai CS; Parker W; Channick RN; Morrell NW; Elliott CG; Yu PB
    Pulm Circ; 2013 Apr; 3(2):369-80. PubMed ID: 24015338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eye signs as a novel risk predictor in pulmonary arterial hypertension associated with systemic lupus erythematosus.
    Li J; Xiong J; Liu P; Peng Y; Cai S; Fang X; Yu S; Zhao J; Wu R
    Adv Rheumatol; 2024 Feb; 64(1):15. PubMed ID: 38424650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.